La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NeuroMetrix Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di NeuroMetrix.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.7%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

NeuroMetrix reports Q3 results

Oct 20

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Sep 09

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché NeuroMetrix non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:NURO - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	4	-8	-7	-7	N/A
3/31/2024	5	-8	-7	-7	N/A
12/31/2023	6	-7	-6	-6	N/A
9/30/2023	6	-6	-6	-6	N/A
6/30/2023	7	-5	-6	-6	N/A
3/31/2023	8	-5	-6	-6	N/A
12/31/2022	8	-4	-5	-5	N/A
9/30/2022	8	-5	-4	-4	N/A
6/30/2022	8	-4	-3	-3	N/A
3/31/2022	8	-3	-3	-3	N/A
12/31/2021	8	-2	-2	-2	N/A
9/30/2021	8	-2	-1	-1	N/A
6/30/2021	8	-1	-1	-1	N/A
3/31/2021	7	-1	-1	-1	N/A
12/31/2020	7	-2	-2	-2	N/A
9/30/2020	7	-3	-2	-2	N/A
6/30/2020	7	-4	-4	-4	N/A
3/31/2020	8	-6	-5	-5	N/A
12/31/2019	9	-4	-4	-4	N/A
9/30/2019	11	-6	-4	-4	N/A
6/30/2019	13	-3	-2	-2	N/A
3/31/2019	14	1	1	1	N/A
12/31/2018	16	0	3	3	N/A
9/30/2018	17	0	0	0	N/A
6/30/2018	17	-7	-3	-3	N/A
3/31/2018	18	-11	N/A	-7	N/A
12/31/2017	17	-20	N/A	-13	N/A
9/30/2017	16	-20	N/A	-13	N/A
6/30/2017	16	-17	N/A	-14	N/A
3/31/2017	14	-38	N/A	-15	N/A
12/31/2016	12	-35	N/A	-15	N/A
9/30/2016	11	-43	N/A	-15	N/A
6/30/2016	10	-42	N/A	-15	N/A
3/31/2016	8	-23	N/A	-14	N/A
12/31/2015	7	-21	N/A	-13	N/A
9/30/2015	6	-13	N/A	-12	N/A
6/30/2015	5	-11	N/A	-10	N/A
3/31/2015	5	-12	N/A	-9	N/A
12/31/2014	6	-11	N/A	-8	N/A
9/30/2014	6	-12	N/A	-7	N/A
6/30/2014	5	-11	N/A	-6	N/A
3/31/2014	5	-8	N/A	-6	N/A
12/31/2013	5	-9	N/A	-7	N/A
9/30/2013	5	-7	N/A	-8	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista NURO è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di NURO cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di NURO cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di NURO cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di NURO cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di NURO è previsto essere elevato tra 3 anni

NeuroMetrix Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023)

NeuroMetrix, Inc. has completed a Follow-on Equity Offering in the amount of $0.692831 million.

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

New major risk - Shareholder dilution

RS Fund Discloses its Views on NeuroMetrix

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.96 loss in FY 2022)

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

New minor risk - Share price stability

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix reports Q3 results

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Senior VP recently sold US$528k worth of stock

Senior VP recently sold US$271k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: US$3.76

New 90-day high: US$3.05

New 90-day high: US$1.86

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - US$1.72

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita